India Pharma Outlook Team | Thursday, 16 October 2025
AstraZeneca Pharma India Limited will be introducing Lokelma (Sodium Zirconium Cyclosilicate powder) for oral suspension in November 2025. The new drug will be a source of relief for adult patients suffering from hyperkalaemia, that is, those who have elevated levels of potassium in their blood.
The 5g product of Lokelma was given permission for import and marketing by DCGI in March 2025. Although the approval for the 5g and 10g versions was given, only the 5g dosage will be launched initially by the company.
The product will be a physician's and patient's a safe, effective, and convenient means to manage hyperkalaemia, leading to better clinical outcomes and patient care.
It is as if we are looking through the company's therapeutic portfolio when we see them dedicating themselves to resolving the most pressing medical needs of India by AstraZeneca Pharma India, and that is what this launch is all about.
Also Read: Syngene Unveils Upgraded Labs to Speed Drug Discovery
Besides, by introducing new drugs to the Indian market, the company has been able to carve a niche for itself in specialty pharmaceuticals, mainly those that deal with chronic and life-threatening conditions.
With this launch, AstraZeneca pharma India is not only remaining true to its philosophy but also uses the opportunity to strengthen its market leadership position and to extend its influence as a force to reckon with in the field of cardiovascular and renal care by delivering advanced therapies.
